|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.54 DKK | +1.92% |
|
+5.35% | -1.44% |
| 04-13 | Lundbeck to present new neurology data at upcoming congress | FW |
| 03-23 | H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.97 | 4.7 | 5.45 | 5.81 | 6.7 | |||||
Return on Total Capital | 5.79 | 6.79 | 7.76 | 8.08 | 9.39 | |||||
Return On Equity % | 7.48 | 9.81 | 10.69 | 13.36 | 12.79 | |||||
Return on Common Equity | 7.48 | 9.81 | 10.69 | 13.36 | 12.79 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 77.85 | 78.35 | 77.48 | 80.78 | 82.68 | |||||
SG&A Margin | 40.65 | 42.87 | 43.72 | 42.87 | 37.46 | |||||
EBITDA Margin % | 23.73 | 24.29 | 26.04 | 28.06 | 31.08 | |||||
EBITA Margin % | 22 | 22.73 | 24.52 | 26.69 | 29.9 | |||||
EBIT Margin % | 13.76 | 14.87 | 16.39 | 19.94 | 23.88 | |||||
Income From Continuing Operations Margin % | 8.09 | 10.5 | 11.5 | 14.28 | 12.96 | |||||
Net Income Margin % | 8.09 | 10.5 | 11.5 | 14.28 | 12.96 | |||||
Net Avail. For Common Margin % | 8.09 | 10.5 | 11.5 | 14.28 | 12.96 | |||||
Normalized Net Income Margin | 7.69 | 8.7 | 9.7 | 12.6 | 13.16 | |||||
Levered Free Cash Flow Margin | 18.94 | 2.75 | 14.75 | 20.71 | 15.99 | |||||
Unlevered Free Cash Flow Margin | 19.53 | 3.1 | 14.92 | 21.03 | 17.3 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.46 | 0.51 | 0.53 | 0.47 | 0.45 | |||||
Fixed Assets Turnover | 7.19 | 8.05 | 8.89 | 9.54 | 11.73 | |||||
Receivables Turnover (Average Receivables) | 6.5 | 7.06 | 7.02 | 6.88 | 7 | |||||
Inventory Turnover (Average Inventory) | 1.46 | 1.12 | 1.06 | 1.01 | 1.01 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.98 | 1.39 | 1.66 | 1.52 | 1.44 | |||||
Quick Ratio | 0.59 | 0.87 | 1.08 | 1.01 | 0.9 | |||||
Operating Cash Flow to Current Liabilities | 0.26 | 0.43 | 0.51 | 0.39 | 0.62 | |||||
Days Sales Outstanding (Average Receivables) | 56.12 | 51.69 | 52 | 53.2 | 52.14 | |||||
Days Outstanding Inventory (Average Inventory) | 249.57 | 326.89 | 344.78 | 363.84 | 361.83 | |||||
Average Days Payable Outstanding | 330.77 | 300.06 | 324.83 | 424.39 | 346.69 | |||||
Cash Conversion Cycle (Average Days) | -25.09 | 78.52 | 71.95 | -7.35 | 67.28 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 29.12 | 26.85 | 18.83 | 66.75 | 46.8 | |||||
Total Debt / Total Capital | 22.55 | 21.17 | 15.85 | 40.03 | 31.88 | |||||
LT Debt/Equity | 28.64 | 26.43 | 18.44 | 66.42 | 46.5 | |||||
Long-Term Debt / Total Capital | 22.19 | 20.83 | 15.52 | 39.83 | 31.68 | |||||
Total Liabilities / Total Assets | 47.25 | 44.52 | 41.07 | 56.1 | 52.16 | |||||
EBIT / Interest Expense | 14.66 | 26.35 | 60.44 | 38.82 | 11.44 | |||||
EBITDA / Interest Expense | 25.82 | 43.89 | 97.7 | 55.42 | 15.07 | |||||
(EBITDA - Capex) / Interest Expense | 23.14 | 40.29 | 92.57 | 50.93 | 13.99 | |||||
Total Debt / EBITDA | 1.35 | 1.23 | 0.79 | 2.67 | 1.5 | |||||
Net Debt / EBITDA | 0.77 | 0.45 | -0.16 | 1.92 | 1.06 | |||||
Total Debt / (EBITDA - Capex) | 1.5 | 1.34 | 0.83 | 2.9 | 1.62 | |||||
Net Debt / (EBITDA - Capex) | 0.86 | 0.49 | -0.17 | 2.09 | 1.14 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -7.77 | 11.95 | 9.13 | 10.51 | 11.93 | |||||
Gross Profit, 1 Yr. Growth % | -6.38 | 12.67 | 7.92 | 12.82 | 14.58 | |||||
EBITDA, 1 Yr. Growth % | -19.37 | 14.61 | 13.48 | 11.99 | 27.08 | |||||
EBITA, 1 Yr. Growth % | -20.32 | 15.7 | 13.93 | 12.71 | 28.71 | |||||
EBIT, 1 Yr. Growth % | -22.33 | 21 | 14.45 | 22.17 | 38.82 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -16.64 | 45.37 | 19.52 | 37.25 | 1.56 | |||||
Net Income, 1 Yr. Growth % | -16.64 | 45.37 | 19.52 | 37.25 | 1.56 | |||||
Normalized Net Income, 1 Yr. Growth % | -26.31 | 26.73 | 15.3 | 29.89 | 11.12 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -16.66 | 45.44 | 19.6 | 37.35 | 1.5 | |||||
Accounts Receivable, 1 Yr. Growth % | -3.68 | 10.17 | 9.45 | 15.75 | 5.04 | |||||
Inventory, 1 Yr. Growth % | 28.29 | 33.49 | 9.42 | -10.03 | 12.3 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 2.41 | -2.57 | 0.45 | 5.34 | -22.53 | |||||
Total Assets, 1 Yr. Growth % | -3.82 | 8.08 | -0.12 | 52.31 | -9.72 | |||||
Tangible Book Value, 1 Yr. Growth % | -22.45 | -61.51 | -178.62 | -1.22K | -32.1 | |||||
Common Equity, 1 Yr. Growth % | 7.69 | 13.68 | 6.09 | 13.45 | -0.43 | |||||
Cash From Operations, 1 Yr. Growth % | -40.79 | 54.89 | 15.94 | -18.48 | 64.79 | |||||
Capital Expenditures, 1 Yr. Growth % | 12.64 | -9.51 | -25.34 | 83.39 | 9.06 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 9.48 | -83.78 | 400.11 | 45.07 | -11.73 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 8.52 | -82.24 | 355.87 | 45.76 | -6.02 | |||||
Dividend Per Share, 1 Yr. Growth % | -20 | 45 | 20.69 | 35.71 | 21.05 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -2.19 | 1.61 | 10.53 | 9.82 | 11.22 | |||||
Gross Profit, 2 Yr. CAGR % | -1.94 | 2.7 | 10.27 | 11.51 | 13.7 | |||||
EBITDA, 2 Yr. CAGR % | -14.31 | -3.87 | 15.81 | 16.23 | 17.84 | |||||
EBITA, 2 Yr. CAGR % | -15.69 | -3.98 | 16.71 | 17.05 | 18.9 | |||||
EBIT, 2 Yr. CAGR % | -21.79 | -3.06 | 20.63 | 24.02 | 27.98 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -24.51 | 10.09 | 31.81 | 28.08 | 18.06 | |||||
Net Income, 2 Yr. CAGR % | -24.51 | 10.09 | 31.81 | 28.08 | 18.06 | |||||
Normalized Net Income, 2 Yr. CAGR % | -25.01 | -3.36 | 24.12 | 28.69 | 23.21 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -24.53 | 10.13 | 31.88 | 28.17 | 18.07 | |||||
Accounts Receivable, 2 Yr. CAGR % | -5.75 | 3.01 | 9.81 | 12.56 | 10.27 | |||||
Inventory, 2 Yr. CAGR % | 12.21 | 36.77 | 20.85 | -0.78 | 0.52 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 0.88 | -0.11 | -1.07 | 2.87 | -9.66 | |||||
Total Assets, 2 Yr. CAGR % | -4.67 | 1.96 | 3.9 | 23.34 | 17.96 | |||||
Tangible Book Value, 2 Yr. CAGR % | -31.3 | -45.36 | -44.99 | 196.77 | 183.53 | |||||
Common Equity, 2 Yr. CAGR % | 4.36 | 10.65 | 9.82 | 9.71 | 6.28 | |||||
Cash From Operations, 2 Yr. CAGR % | -6.68 | -4.23 | 34.01 | -2.78 | 15.9 | |||||
Capital Expenditures, 2 Yr. CAGR % | 7.32 | 0.96 | -17.8 | 17.02 | 41.42 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -0.63 | -57.85 | -2.48 | 178.57 | 11.99 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 0.27 | -56.1 | -3.4 | 166.49 | 15.85 | |||||
Dividend Per Share, 2 Yr. CAGR % | -30.16 | 7.7 | 32.29 | 27.98 | 28.17 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -3.46 | 2.31 | 4.06 | 10.52 | 10.52 | |||||
Gross Profit, 3 Yr. CAGR % | -4.7 | 2.7 | 4.41 | 11.89 | 12.52 | |||||
EBITDA, 3 Yr. CAGR % | -15.72 | -5.59 | 2.64 | 16.88 | 18.76 | |||||
EBITA, 3 Yr. CAGR % | -16.81 | -6.31 | 2.77 | 17.88 | 19.78 | |||||
EBIT, 3 Yr. CAGR % | -25.13 | -9.54 | 4.16 | 25.06 | 27.29 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -30.39 | -6.08 | 13.14 | 33.6 | 18.55 | |||||
Net Income, 3 Yr. CAGR % | -30.39 | -6.08 | 13.14 | 33.6 | 18.55 | |||||
Normalized Net Income, 3 Yr. CAGR % | -27.88 | -10.67 | 4.32 | 30.31 | 24.63 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -30.39 | -6.06 | 13.2 | 33.68 | 18.58 | |||||
Accounts Receivable, 3 Yr. CAGR % | -3.82 | -0.72 | 5.11 | 11.75 | 9.99 | |||||
Inventory, 3 Yr. CAGR % | 16.54 | 22.44 | 26.97 | 9.53 | 3.4 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 10.63 | -0.28 | 0.07 | 1.02 | -6.41 | |||||
Total Assets, 3 Yr. CAGR % | 14.62 | -0.6 | 1.26 | 18.03 | 11.6 | |||||
Tangible Book Value, 3 Yr. CAGR % | -10.46 | -43.36 | -38.32 | 50.22 | 84.89 | |||||
Common Equity, 3 Yr. CAGR % | 8.65 | 7.38 | 9.11 | 11.02 | 6.22 | |||||
Cash From Operations, 3 Yr. CAGR % | -27.58 | 10.49 | 2.07 | 13.55 | 15.92 | |||||
Capital Expenditures, 3 Yr. CAGR % | 10.97 | 1.39 | -8.7 | 7.41 | 14.3 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -14.92 | -45.69 | 1.36 | 13.85 | 88.6 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -14.13 | -43.69 | 0.42 | 13.28 | 87 | |||||
Dividend Per Share, 3 Yr. CAGR % | -44.97 | -10.9 | 11.87 | 33.42 | 25.63 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 0.84 | 1.15 | 1.91 | 5.25 | 6.87 | |||||
Gross Profit, 5 Yr. CAGR % | 1.89 | 1.37 | 1.02 | 6.14 | 8.48 | |||||
EBITDA, 5 Yr. CAGR % | 1.25 | -3.93 | -4.3 | 3.23 | 9.8 | |||||
EBITA, 5 Yr. CAGR % | 1.11 | -4.34 | -4.74 | 3.09 | 10.36 | |||||
EBIT, 5 Yr. CAGR % | -0.43 | -8.21 | -9.39 | 3.65 | 15.29 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 1.71 | -6.1 | -10.13 | 6.32 | 15.09 | |||||
Net Income, 5 Yr. CAGR % | 1.71 | -6.1 | -10.13 | 6.32 | 15.09 | |||||
Normalized Net Income, 5 Yr. CAGR % | -1.39 | -8.84 | -10.39 | 4.47 | 13.77 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 1.57 | -6.17 | -10.11 | 6.37 | 15.12 | |||||
Accounts Receivable, 5 Yr. CAGR % | -4.54 | -1.48 | 1.41 | 4.39 | 7.14 | |||||
Inventory, 5 Yr. CAGR % | 12.68 | 24.07 | 20.36 | 12.56 | 15.64 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 2.62 | 5.01 | 5.79 | 0.97 | -3.94 | |||||
Total Assets, 5 Yr. CAGR % | 11.39 | 13.65 | 10.21 | 8.36 | 7.64 | |||||
Tangible Book Value, 5 Yr. CAGR % | 39.22 | -17.91 | -26.31 | 9.86 | 13.54 | |||||
Common Equity, 5 Yr. CAGR % | 13.52 | 11.27 | 9.12 | 8.31 | 7.97 | |||||
Cash From Operations, 5 Yr. CAGR % | -6.18 | -2.75 | -7.36 | 4.98 | 7.39 | |||||
Capital Expenditures, 5 Yr. CAGR % | 11.49 | 8.65 | -1.58 | 7.37 | 8.76 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -0.75 | -25.18 | -10.15 | 7.82 | 6.91 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -0.37 | -23.78 | -9.99 | 7.88 | 7.75 | |||||
Dividend Per Share, 5 Yr. CAGR % | -3.98 | -18.37 | -21.84 | 2.99 | 18.13 |
- Stock Market
- Equities
- HLUN B Stock
- Financials H. Lundbeck A/S
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















